Riluzole is the only FDA approved drug for the treatment of amyotrophic lateral sclerosis
(ALS). However, the drug affords moderate protection to ALS patients, extending life for a …

Amyotrophic lateral sclerosis is caused by selective degeneration of motor neurons in the
brain and spinal cord. There are still no other effective therapies 10 years after the approval …

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease associated
with a life expectancy of approximately 3 years after symptom onset, but the range of survival …

Introduction: Amyotrophic lateral sclerosis (ALS) is a rapidly progressing neurodegenerative
disease leading almost irrevocably to paralysis and death within 5 years after the first …

Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) are
neurodegenerative disorders, related by signs of deteriorating motor and cognitive functions …

Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive and fatal motor neuron
disease. We carried out two randomized, double‐blind, placebo‐controlled, multi‐centre …

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that leads to death
by progressive paralysis and respiratory failure within 2-4 years of onset. About 90-95% of …

Abstract Amyotrophic Lateral Sclerosis (ALS) is recognized as a very complex disease. As
we have learned in the past 20 years from studies in patients and in models based on the …

Amyotrophic lateral sclerosis (ALS) is a devastating and fatal neurodegenerative disease of
adults which preferentially attacks the neuromotor system. Riluzole has been used as the …

It has been eight years since the Food and Drug Administration approved riluzole as the
only drug of established value in slowing disease progression for patients with ALS. The …